Glucagon-like Peptide-1 (GLP-1) and Protective Effects in Cardiovascular Disease: A New Therapeutic Approach for Myocardial Protection

Role of Insulin Resistance in Human Disease

Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154 · see citing works

Banting lecture 1988. Role of insulin resistance in human disease.

Reaven, G. (1988) · Diabetes · doi:10.2337/diabetes.37.12.1595 · Cited by 3,801 · see citing works

Ischemia and reperfusion—from mechanism to translation

Eltzschig, H. K., & Eckle, T. D. L. G. (2011) · Nature Medicine · doi:10.1038/nm.2507 · Cited by 3,389 · see citing works

How MAP Kinases Are Regulated

Cobb, M. H., & Goldsmith, E. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.25.14843 · Cited by 1,718 · see citing works

Transcriptional Regulation by Extracellular signals: Mechanisms and Specificity

Hill, C. S., & Treisman, R. (1995) · Cell · doi:10.1016/0092-8674(95)90403-4 · Cited by 1,263 · see citing works

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · see citing works

The MAP kinase cascade is essential for diverse signal transduction pathways

Nishida, E., & Gotoh, Y. (1993) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(93)90019-j · Cited by 1,087 · see citing works

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · see citing works

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · see citing works

Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family

Wang, Y., Huang, S., Sah, V. P., Ross, J., Brown, J. H., Han, J., & Chien, K. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.2161 · Cited by 842 · see citing works

Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking Tale

Rose, B. A., Force, T. L., & Wang, Y. (2010) · Physiological Reviews · doi:10.1152/physrev.00054.2009 · Cited by 720 · see citing works

Mechanisms of action of glucagon-like peptide 1 in the pancreas

Doyle, M. E., & Egan, J. M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 679 · see citing works

Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure

Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654 · see citing works

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

Bose, A. K., Mocanu, M., Carr, R. D., Brand, C. L., & Yellon, D. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 642 · see citing works

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor

Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/endo.137.7.8770921 · Cited by 618 · see citing works

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.

Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J., Lopez, M. E., Hollenberg, A., Baggio, L., Saper, C., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15595 · Cited by 544 · see citing works

Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System

Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 539 · see citing works

Insulin Resistance in Chronic Heart Failure: Relation to Severity and Etiology of Heart Failure

Swan, J. W., Anker, S. D., Walton, C., Godsland, I. F., Clark, A. L., Leyva, F., Stevenson, J. C., & Coats, A. J. S. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00185-x · Cited by 532 · see citing works

“Stress-Responsive” Mitogen-Activated Protein Kinases (c-Jun N-Terminal Kinases and p38 Mitogen-Activated Protein Kinases) in the Myocardium

Sugden, P. H., & Clerk, A. (1998) · Circulation Research · doi:10.1161/01.res.83.4.345 · Cited by 519 · see citing works

GLP-1 receptor activation and epac2 link atrial natriuretic peptide secretion to control of blood pressure

Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · see citing works

Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias

Oliver, E. F., & Opie, L. H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90939-3 · Cited by 506 · see citing works

Inhibition of p38 Mitogen-Activated Protein Kinase Decreases Cardiomyocyte Apoptosis and Improves Cardiac Function After Myocardial Ischemia and Reperfusion

Ma, X. L., Kumar, S., Gao, F., Louden, C. S., Lopez, B. L., Christopher, T. A., Wang, C., Lee, J. C., Feuerstein, G., & Yue, T. (1999) · Circulation · doi:10.1161/01.cir.99.13.1685 · Cited by 501 · see citing works

Biological actions and therapeutic potential of the glucagon-like peptides

Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 500 · see citing works

MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets

Muslin, A. J. (2008) · Clinical Science · doi:10.1042/cs20070430 · Cited by 496 · see citing works

Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis

Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 484 · see citing works

Tissue-specific expression of the human receptor for glucagon-like peptide-I: Brain, heart and pancreatic forms have the same deduced amino acid sequences

Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450 · see citing works

Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts

Zhao, T., Parikh, P., Bhashyam, S., Bölükoglu, H., Poornima, I. G., Shen, Y., & Shannon, R. P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.100982 · Cited by 298 · see citing works

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

Yu, M., Moreno, C., Hoagland, K. M., Dahly, A., Ditter, K., Mistry, M., & Roman, R. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00012 · Cited by 292 · see citing works

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · see citing works

Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat

Stoffers, D. A., Desai, B. M., León, D. D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261 · see citing works

Effect of Glucagon-Like Peptide-1 (GLP-1) on Glycemic Control and Left Ventricular Function in Patients Undergoing Coronary Artery Bypass Grafting

Sokos, G. G., Bölükoglu, H., German, J., Hentosz, T. M., Magovern, G. J., Maher, T. D., Dean, D. A., Bailey, S. H., MARRONE, G. C., Benckart, D. H., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.022 · Cited by 253 · see citing works

Protein Kinase Cζ Activation Mediates Glucagon-Like Peptide-1–Induced Pancreatic β-Cell Proliferation

Buteau, J., Foisy, S., Rhodes, C. J., Carpenter, L., Biden, T. J., & Prentki, M. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2237 · Cited by 252 · see citing works

Targeted Inhibition of p38 Mitogen-activated Protein Kinase Antagonizes Cardiac Injury and Cell Death Following Ischemia-Reperfusion in Vivo

Kaiser, R. A., Bueno, O. F., Lips, D. J., Doevendans, P. A., Jones, F. S., Kimball, T. F., & Molkentin, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313717200 · Cited by 231 · see citing works

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies

Blonde, L., & Russell-Jones, D. L. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01075.x · Cited by 227 · see citing works

The Heart: Physiology and Metabolism

(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-4-336_3 · Cited by 195 · see citing works

Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor

Gros, R., You, X., Baggio, L. L., Kabir, M. G., Sadi, A. M., Mungrue, I. N., Parker, T. G., Huang, Q., Drucker, D. J., & Husain, M. (2003) · Endocrinology · doi:10.1210/en.2003-0007 · Cited by 192 · see citing works

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

Nyström, T., Gonon, A. T., Sjöholm, Å., & Pernow, J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.024 · Cited by 188 · see citing works

Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes

Okerson, T. E., Yan, P., Stonehouse, A. H., & Brodows, R. G. (2009) · American Journal of Hypertension · doi:10.1038/ajh.2009.245 · Cited by 186 · see citing works

Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

Poornima, I. G., Brown, S. B., Bhashyam, S., Parikh, P., Bölükoglu, H., & Shannon, R. P. (2008) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.766402 · Cited by 182 · see citing works

Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes

Petroff, M. V., Egan, J. M., Wang, X., & Sollott, S. J. (2001) · Circulation Research · doi:10.1161/hh1701.095716 · Cited by 180 · see citing works

Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways

Sun, H.-Y., Wang, N.-P., Halkos, M. E., Kerendi, F., Kin, H., Guyton, R. A., Vinten‐Johansen, J., & Zhao, Z. (2006) · APOPTOSIS · doi:10.1007/s10495-006-9037-8 · Cited by 174 · see citing works

Cocaine Cardiotoxicity

Phillips, K. R. B., Luk, A. C., Soor, G. S., Abraham, J. R., Leong, S. W., & BUTANY, J. W. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256574 · Cited by 162 · see citing works

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat

Golpon, H. A., Püchner, A., Welte, T., von Wichert, P., & Feddersen, C. O. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(01)00300-7 · Cited by 158 · see citing works

Mineralocorticoid Receptor–Mediated Vascular Insulin Resistance

Bender, S. B., McGraw, A. P., Jaffe, I. Z., & Sowers, J. R. (2013) · Diabetes · doi:10.2337/db12-0905 · Cited by 158 · see citing works

Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction

Levantesi, G., Macchia, A., Marfisi, R., Franzosi, M. G., Maggioni, A. P., Nicolosi, G. L., Schweiger, C., Tavazzi, L., Tognoni, G., Valagussa, F., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.062 · Cited by 157 · see citing works

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP

Green, B. D., Hand, K. V., Dougan, J. E., McDonnell, B. M., Cassidy, R. S., & Grieve, D. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.08.001 · Cited by 152 · see citing works

Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways

Friedrichsen, B. N., Neubauer, N., Lee, Y. C., Gram, V. K., Blume, N., Petersen, J. S., Nielsen, J. H., & Møldrup, A. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06160 · Cited by 147 · see citing works

New insights into insulin resistance in the diabetic heart

Gray, S., & Kim, J. K. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2011.05.001 · Cited by 143 · see citing works

Adenosine A 1 Receptor Induced Delayed Preconditioning in Rabbits

Dana, A., Skarli, M., Papakrivopoulou, J., & Yellon, D. M. (2000) · Circulation Research · doi:10.1161/01.res.86.9.989 · Cited by 138 · see citing works

Endoplasmic Reticulum Stress as a Novel Therapeutic Target in Heart Diseases

Tóth, A., Nickson, P., Mandl, A., Bannister, M. L., Tóth, K., & Erhardt, P. (2007) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152907781745260 · Cited by 131 · see citing works

Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.

Barragán, J., Rodríguez, R. E., Eng, J., & Blázquez, E. (1996) · Regulatory Peptides · doi:10.1016/s0167-0115(96)00113-9 · Cited by 127 · see citing works

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats

Pacheco, B. P. M., Crajoinas, R. O., Couto, G. K., Davel, A. P., Lessa, L. M. A., Rossoni, L. V., & Girardi, A. C. C. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328341939d · Cited by 124 · see citing works

Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway

Bose, A., Mocanu, M. M., Carr, R. D., & Yellon, D. M. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6030-6 · Cited by 123 · see citing works

The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning

Steenbergen, C. (2002) · Basic Research in Cardiology · doi:10.1007/s00395-002-0364-9 · Cited by 119 · see citing works

A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in Humans

Read, P. A., Hoole, S. P., White, P. A., Khan, F. Z., O'Sullivan, M., West, N. E. J., & Dutka, D. P. (2011) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.110.960476 · Cited by 119 · see citing works

Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options.

Phillips, K. R. B., Luk, A. C., Soor, G. S., Abraham, J. R., Leong, S. W., & BUTANY, J. W. (2009) · PubMed · doi:10.2165/00129784-200909030-00005 · Cited by 118 · see citing works

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

Read, P. A., Khan, F. Z., & Dutka, D. P. (2011) · Heart · doi:10.1136/hrt.2010.219345 · Cited by 114 · see citing works

p38 Triggers Late Preconditioning Elicited by Anisomycin in Heart

Zhao, T. C., Taher, M. M., Valerie, K. C., & Kukreja, R. C. (2001) · Circulation Research · doi:10.1161/hh2201.099452 · Cited by 105 · see citing works

Decreased GLUT-4 mRNA content and insulin-sensitive deoxyglucose uptake show insulin resistance in the hypertensive rat heart

Paternostro, G., Clarke, K. J., Heath, J. K., Seymour, A.-M. L., & Radda, G. K. (1995) · Cardiovascular Research · doi:10.1016/s0008-6363(95)00019-4 · Cited by 101 · see citing works

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

Kelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J., Katz, H., & Bank, A. J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-64 · Cited by 98 · see citing works

Role of p38 Mitogen-Activated Protein Kinases in Preconditioning

Ping, P., & Murphy, E. (2000) · Circulation Research · doi:10.1161/01.res.86.9.921 · Cited by 95 · see citing works

Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions

Asghar, O., Alam, U., Hayat, S. A., Aghamohammadzadeh, R., Heagerty, A. M., & Malik, R. A. (2012) · Current Cardiology Reviews · doi:10.2174/157340312803760749 · Cited by 93 · see citing works

The Association of Heart Failure With Insulin Resistance and the Development of Type 2 Diabetes

Kostis, J. B., & SANDERS, M. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.11.038 · Cited by 92 · see citing works

Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium

Kavianipour, M., Ehlers, M. R., Malmberg, K., Ronquist, G., Rydén, L., Wikström, G., & Gutniak, M. (2003) · Peptides · doi:10.1016/s0196-9781(03)00108-6 · Cited by 90 · see citing works

Short-Term Effects of Liraglutide on Visceral Fat Adiposity, Appetite, and Food Preference: A Pilot Study of Obese Japanese Patients with Type 2 Diabetes

Inoue, K., Maeda, N., Kashine, S., Fujishima, Y., Kozawa, J., Hiuge-Shimizu, A., Okita, K., Imagawa, A., Funahashi, T., & Shimomura, I. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-109 · Cited by 89 · see citing works

p38 MAP kinase is a mediator of ischemic preconditioning in pigs

Schulz, R. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00319-x · Cited by 86 · see citing works

Overexpression of Mitogen-activated Protein Kinase Kinase 6 in the Heart Improves Functional Recovery from Ischemia in Vitro and Protects against Myocardial Infarction in Vivo

Martindale, J. J., Wall, J. A., Martinez-Longoria, D. M., Aryal, P., Rockman, H. A., Guo, Y., Bolli, R., & Glembotski, C. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406690200 · Cited by 85 · see citing works

Adenosine-induced late preconditioning in mouse hearts: role of p38 MAP kinase and mitochondrial KATPchannels

Zhao, T. C., Hines, D. S., & Kukreja, R. C. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.280.3.h1278 · Cited by 83 · see citing works

Antiischemic Effects of SB203580 Are Mediated Through the Inhibition of p38α Mitogen-Activated Protein Kinase

Martin, J. W., Avkiran, M., Quinlan, R. A., Cohen, P., & Marber, M. S. (2001) · Circulation Research · doi:10.1161/hh2101.099504 · Cited by 74 · see citing works

Impaired p38 MAPK/HSP27 signaling underlies aging-related failure in opioid-mediated cardioprotection

Peart, J. N., Gross, E. R., Headrick, J. P., & Gross, G. J. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.02.011 · Cited by 71 · see citing works

Disruption of a single copy of the p38α MAP kinase gene leads to cardioprotection against ischemia–reperfusion

Otsu, K., Yamashita, N., Nishida, K., Hirotani, S., Yamaguchi, O., Watanabe, T., Hikoso, S., Higuchi, Y., Matsumura, Y., Maruyama, M., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00096-2 · Cited by 70 · see citing works

Activation of mitogen‐activated protein kinases (p38‐MAPKs, SAPKs/JNKs and ERKs) by adenosine in the perfused rat heart

Haq, S. E. A., Clerk, A., & Sugden, P. H. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01000-x · Cited by 66 · see citing works

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes

Fujishima, Y., Maeda, N., Inoue, K., Kashine, S., Nishizawa, H., Hirata, A., Kozawa, J., Yasuda, T., Okita, K., Imagawa, A., et al. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-107 · Cited by 66 · see citing works

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

Liu, Q., Adams, L. A., Broyde, A., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-32 · Cited by 66 · see citing works

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

Li, C., Li, J., Zhang, Q.-M., Lv, L., Chen, R., Lv, C.-F., Yu, P., & Yu, D. M. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-142 · Cited by 64 · see citing works

Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway

Liu, J., Liu, Y., Chen, L., Wang, Y., & Li, J. (2013) · Journal of Diabetes Research · doi:10.1155/2013/630537 · Cited by 48 · see citing works

Endoplasmic reticulum stress and the on site function of resident PTP1B

Popov, D. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.048 · Cited by 42 · see citing works

Antimycin A induced cardioprotection is dependent on pre-ischemic p38-MAPK activation but independent of MKK3

KABIR, A., Cao, X. B., Gorog, D. A., Tanno, M., BASSI, R., Bellahcene, M., Quinlan, R. A., Davis, R. J., Flavell, R. A., & Shattock, M. J. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.07.012 · Cited by 18 · see citing works

Pressure overload induces greater hypertrophy and mortality in female mice with p38α MAPK inhibition

Liu, J., Sadoshima, J., Zhai, P., Hong, C., Yang, G., Chen, W., Yan, L., Wang, Y., Vatner, S. F., & Vatner, D. E. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.07.007 · Cited by 15 · see citing works

Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice

Chen, Y., Du, J., Zhao, Y., Zhang, L., Lv, G., Zhuang, S., Qin, G., & Zhao, T. C. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0262-8 · Cited by 156 · see citing works

The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome

Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148 · see citing works

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143 · see citing works

AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes

Balteau, M., Steenbergen, A. V., Timmermans, A. D., Dessy, C., Behets-Wydemans, G., Tajeddine, N., Castanares‐Zapatero, D., Gilon, P., Vanoverschelde, J., Horman, S., et al. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00210.2014 · Cited by 121 · see citing works

Sensory Nutrition and Bitterness and Astringency of Polyphenols

Osakabe, N., Shimizu, T., Fujii, Y., Fushimi, T., & Calabrese, V. (2024) · Biomolecules · doi:10.3390/biom14020234 · Cited by 98 · see citing works

Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients

Li, C.-J., Yu, Q., Yu, P., Yu, T.-L., Zhang, Q., Lu, S., & Yu, D.-M. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-36 · Cited by 90 · see citing works

A Prospective Randomized Controlled Trial of the Metabolic Effects of Sleeve Gastrectomy with Transit Bipartition

de Azevedo, F. R., Santoro, S., Corrêa‐Giannella, M. L., Toyoshima, M. T. K., Giannella‐Neto, D., Calderaro, D., Gualandro, D. M., Yu, P. C., & Caramelli, B. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3239-3 · Cited by 86 · see citing works

GLP-1 receptor agonists and heart failure in diabetes

Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30068-x · Cited by 65 · see citing works

Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium

DeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., Qin, G., Zhuang, S., & Zhao, T. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00109.2014 · Cited by 62 · see citing works

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58 · see citing works

Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1

Zhao, T., Chen, H., Cheng, C., Zhang, J., Yan, Z., Kuang, J., Kong, F., Li, C., & Lu, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109224 · Cited by 52 · see citing works

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus

Onoviran, O. F., Li, D., Smith, S. T., & Raji, M. A. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319862691 · Cited by 59 · see citing works

Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach

Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53 · see citing works

Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study

Faber, R., Zander, M., Peña, A., Michelsen, M. M., Mygind, N. D., & Prescott, E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0206-3 · Cited by 51 · see citing works

2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists

HOCKING, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., Story, D., Greenfield, J. R., Boussioutas, A., Devereaux, B., Andrikopoulos, S., Shaw, J. E., et al. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355288 · Cited by 48 · see citing works

Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway

Chang, G., Liu, J., Qin, S., Jiang, Y., Zhang, P., Yu, H., Lü, K., Zhang, N., Cao, L., Wang, Y., et al. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3318 · Cited by 48 · see citing works

Mechanisms Involved in Cardioprotection Induced by Physical Exercise

Penna, C. R. R., Alloatti, G., & Crisafulli, A. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.8009 · Cited by 44 · see citing works

GLP-1: benefits beyond pancreas

Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 41 · see citing works

Endogenous Cardioprotective Agents: Role in Pre and Postconditioning

Penna, C. R. R., Granata, R., Tocchetti, C. G., Gallo, M. P., Alloatti, G., & Pagliaro, P. (2015) · Current Drug Targets · doi:10.2174/1389450116666150309115536 · Cited by 37 · see citing works

Gastrointestinal Hormones ☆

Gribble, F. M., Reimann, F. M., & Roberts, G. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00002-5 · Cited by 27 · see citing works

Development of novel ligands for peptide GPCRs

Moran, B. M., McKillop, A. M., & O'Harte, F. P. M. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.009 · Cited by 24 · see citing works

Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus

McCormick, L. M., Heck, P. M., Ring, L. S., Kydd, A. C., Clarke, S. J., Hoole, S. P., & Dutka, D. P. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0259-3 · Cited by 23 · see citing works

PEGylated Exendin-4, a Modified GLP-1 Analog Exhibits More Potent Cardioprotection than Its Unmodified Parent Molecule on a Dose to Dose Basis in a Murine Model of Myocardial Infarction

Sun, Z., Tong, G., Kim, T. H., Ma, N., Niu, G., Cao, F., & Chen, X. S. (2014) · Theranostics · doi:10.7150/thno.10226 · Cited by 23 · see citing works

GLP-1-mediated gene therapy approaches for diabetes treatment

Tasyurek, H. M., Altunbaş, H., Canatan, H., Griffith, T. S., & Şanlıoğlu, S. (2014) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2014.7 · Cited by 21 · see citing works

Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure

Lopez, P. D., Bhatia, K., Bohra, C., Mahmood, K., Baruch, L., & Eng, C. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.07.012 · Cited by 21 · see citing works

Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy

Fan, D., Wang, Y., Liu, B., & Yin, F. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000807 · Cited by 19 · see citing works

DPP4 Deficiency Preserved Cardiac Function in Abdominal Aortic Banding Rats

Ku, H.-C., & Su, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085634 · Cited by 19 · see citing works

Gastrointestinal hormone-mediated beneficial bioactivities of bitter polyphenols

Osakabe, N., Ohmoto, M., Shimizu, T., Iida, N., Fushimi, T., Fujii, Y., Abe, K., & Calabrese, V. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104550 · Cited by 17 · see citing works

Glucagon-like peptide-1 receptor antagonism impairs basal exercise capacity and vascular adaptation to aerobic exercise training in rats

Scalzo, R. L., Knaub, L. A., Hull, S., Keller, A. C., Hunter, K. S., Walker, L. A., & Reusch, J. E. B. (2018) · Physiological Reports · doi:10.14814/phy2.13754 · Cited by 17 · see citing works

Glycemia Lowering and Risk for Heart Failure

Zhong, J., Goud, A., & Rajagopalan, S. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001967 · Cited by 12 · see citing works

Toll-like receptor 4 is necessary for glucose-dependent glucagon-like peptide-1 secretion in male mice

Wang, L., Zhan, X., Wang, Z., Ma, J., Chang, X., & Zhu, X. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.055 · Cited by 11 · see citing works

Interplay Between Systemic Metabolic Cues and Autonomic Output: Connecting Cardiometabolic Function and Parasympathetic Circuits

Espinoza, L., Fedorchak, S., & Boychuk, C. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.624595 · Cited by 10 · see citing works

Effect of Milk Protein–Polyphenol Conjugate on the Regulation of GLP-1 Hormone

Wazzan, H., Abraham, A. N., Saiara, N., Anand, S., Gill, H. S., & Shukla, R. (2024) · Foods · doi:10.3390/foods13121935 · Cited by 10 · see citing works

Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis

Chen, C., Huang, Y., Zeng, Y., Lu, X., & Dong, G. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-01275-5 · Cited by 9 · see citing works

Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets

Correale, M., Tricarico, L., Croella, F., Alfieri, S., Fioretti, F., Brunetti, N. D., Inciardi, R. M., & Nodari, S. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1157472 · Cited by 9 · see citing works

Nuevos agentes terapéuticos para la diabetes tipo 2

Puig‐Domingo, M., & Pellitero, S. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.03.018 · Cited by 7 · see citing works

Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes

OLIVEROS, R. A., Pham, S. V., Bailey, S. R., & CHILTON, R. J. (2014) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2014.10.02.117 · Cited by 6 · see citing works

Glucagon‐Like Peptide‐1 (GLP‐1) Rescue Diabetic Cardiac Dysfuntions in Human iPSC‐Derived Cardiomyocytes

Zhou, Y., Huang, S.-T., CHENG-WU, L., Qiao, Y., Liu, Q., Chen, T., Wang, J., & Liu, Y. (2022) · Advanced Biology · doi:10.1002/adbi.202200130 · Cited by 3 · see citing works

GLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?

Piras, G., Brasili, S., Demontis, D., Sala, L. D., Cocchiara, F., Maggi, D. C., & Arecco, A. (2026) · Diabetology · doi:10.3390/diabetology7030050 · Cited by 2 · see citing works

Cardiac Effects of Glucagon-Like Peptide 1 with Chitosan-Based Scaffold after Inducing Myocardial Infarction in Dogs

Zeraatian, S., Aghdam, R. M., & Hossein, A. S. (2015) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000159 · Cited by 1 · see citing works

Glucagon-like Peptide-1 Levels and Related Parameters in Rheumatoid Arthritis Patients Prone to Atherosclerosis

Shafeeq, N. K., Al-joda, B. M. S., & Tamara Ala, A. (2017) · Ibn AL- Haitham Journal For Pure and Applied Science · doi:10.30526/30.1.1064 · Cited by 1 · see citing works

New therapies for type 2 diabetes mellitus

Puig‐Domingo, M., & Pellitero, S. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.12.030 · Cited by 1 · see citing works

Abstract 18691: Stimulation of Glucagon-Like-Peptide-1 Receptor Through Exendin-4 Preserves Myocardial Performance and Prevents Cardiac Remodeling in Infarcted Myocardium

DeNicola, M., & Zhao, T. C. (2013) · Circulation · doi:10.1161/circ.128.suppl_22.a18691

Impact cardiovasculaire des incrétino-mimétiques chez le diabétique de type 2 : le point en 2015

Buysschaert, M., Amoussou-Guénou, D., Yanogo, D., & Djrolo, F. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30036-5

GLYCEMIC AND NON-GLYCEMIC EFFECTS OF EXENATIDE IN PATIENTS WITH DIABETES MELLITUS OF TYPE 2 (DM2) WITH MYOCARDIAL INFARCTION

Babenko, A. Y., ZYKOV, V. A., & Grineva, E. N. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-9-116-122

Glucagon-Like Peptide-1 and its Cardiovascular Effects

Heo, K., Fujiwara, K., & Abe, J. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0265-9 · Cited by 13 · see citing works

Glucagon-Like Peptide 1—A Cardiologic Dimension

Treiman, M., Elvekjær, M., Engstrøm, T., & Jensen, J. S. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.02.012 · Cited by 27 · see citing works

Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?

Grieve, D., Cassidy, R. S., & Green, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00376.x · Cited by 121 · see citing works

Kardiovaskuläre Effekte inkretinbasierter Therapien

Lehrke, M., & Marx, N. (2012) · Herz · doi:10.1007/s00059-012-3599-8 · Cited by 1 · see citing works

Non-Insulin Injectable Treatments (Glucagon-Like Peptide-1 and Its Analogs) and Cardiovascular Disease

Lebovitz, H. E., & Banerji, M. A. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0022 · Cited by 13 · see citing works